Age-related Macular Degeneration Market - Global Forecast 2026-2032

List of Tables

The Age-related Macular Degeneration Market is projected to grow by USD 21.63 billion at a CAGR of 8.15% by 2032.

KEY MARKET STATISTICS
Base Year [2025]	USD 12.49 billion
Estimated Year [2026]	USD 13.48 billion
Forecast Year [2032]	USD 21.63 billion
CAGR (%)	8.15%

Age-related Macular Degeneration Executive Summary

Age-related macular degeneration (AMD) is a leading cause of irreversible central vision loss among older adults, driven by progressive damage to the macula and strongly associated with aging, genetic susceptibility, smoking, cardiovascular risk factors, and chronic inflammation. The condition is commonly classified as early, intermediate, or late AMD, with late disease presenting as geographic atrophy, neovascular or wet AMD, or both. Because AMD directly affects reading, driving, facial recognition, medication adherence, and independent living, it remains a major public health priority across ophthalmology, optometry, geriatrics, retinal imaging, drug development, and vision rehabilitation.

The clinical and commercial landscape for age-related macular degeneration is shaped by rising life expectancy, wider retinal screening access, improved optical coherence tomography (OCT) imaging, anti-vascular endothelial growth factor (anti-VEGF) treatment protocols, and emerging therapies for geographic atrophy. Verified epidemiological evidence from public health agencies and peer-reviewed ophthalmology studies consistently shows that AMD prevalence increases steeply with age, while clinical guidance identifies smoking cessation, nutritional risk management, early detection, and timely referral as central strategies for reducing avoidable vision loss. As healthcare systems confront the growing burden of chronic eye disease in aging populations, stakeholders are prioritizing durable therapies, efficient monitoring pathways, patient adherence support, and equitable access to specialist retinal care.

Transformative Shifts in the AMD Landscape

The AMD landscape is undergoing a structural shift from late-stage, symptom-driven care toward earlier detection, longitudinal monitoring, and personalized disease management. High-resolution OCT, OCT angiography, fundus autofluorescence, color fundus photography, and home-based vision monitoring are helping clinicians identify retinal fluid, drusen burden, pigmentary abnormalities, choroidal neovascularization, and geographic atrophy progression with greater precision. This diagnostic evolution is strengthening risk stratification and enabling more proactive referral pathways between primary eye care providers and retina specialists.

Therapeutic innovation is also transforming AMD management. For neovascular AMD, intravitreal anti-VEGF therapy remains the core evidence-based treatment approach, with clinical practice increasingly focused on extending treatment intervals, minimizing injection burden, and preserving long-term visual function. For geographic atrophy, the approval of complement-targeting intravitreal therapies in major regulatory settings has created a new treatment category for an AMD subtype that previously had limited disease-modifying options. At the same time, sustained-release delivery, gene-based approaches, biosimilars, combination regimens, and biomarkers for treatment response are changing expectations around durability, adherence, and individualized care.

Care delivery is shifting as well. Retina clinics face capacity pressure from repeated injection visits and imaging follow-ups, while payers and providers seek pathways that maintain outcomes without unnecessary appointments. This is accelerating adoption of treat-and-extend protocols, standardized imaging workflows, teleophthalmology triage, integrated electronic health records, and real-world evidence generation. The most successful industry participants will be those that align clinical efficacy with patient convenience, health-system efficiency, and measurable preservation of vision-related quality of life.

Cumulative Impact of Artificial Intelligence in AMD Care

Artificial intelligence is becoming a practical accelerator in age-related macular degeneration by supporting screening, image interpretation, workflow prioritization, disease progression analysis, and clinical research. Deep learning models trained on retinal photographs, OCT scans, and multimodal imaging can help detect AMD features such as drusen, pigmentary changes, subretinal or intraretinal fluid, and atrophy patterns. In clinical settings, AI-enabled decision support has the potential to flag urgent neovascular conversion, prioritize referrals, reduce reader variability, and support consistent monitoring across high-volume retinal practices.

The cumulative impact of AI is especially important in regions with limited retinal specialists. Automated AMD screening and triage can extend the reach of eye-care programs by enabling primary care, optometry, community clinics, and teleophthalmology networks to identify patients who require specialist evaluation. AI can also enhance clinical trial design by improving lesion segmentation, quantifying geographic atrophy growth, identifying eligible patient subgroups, and standardizing imaging endpoints. These applications are backed by a growing peer-reviewed evidence base showing strong performance of machine learning systems in retinal disease classification when trained and validated on high-quality datasets.

However, responsible AI deployment requires rigorous validation, governance, and clinical oversight. Algorithms can be affected by image quality, device variation, population bias, disease stage imbalance, and inconsistent labeling. Regulatory expectations increasingly emphasize transparency, safety monitoring, data privacy, and post-deployment performance evaluation. For AMD stakeholders, AI should be viewed not as a replacement for clinicians but as an enabling layer that improves access, consistency, operational efficiency, and evidence generation when embedded into clinically validated workflows.

Key Regional Insights Across AMD Care

Europe benefits from established ophthalmic societies, national health systems, retina specialty networks, and active adoption of evidence-based AMD therapies. The region places strong emphasis on cost-effectiveness, treatment pathway optimization, pharmacovigilance, health technology assessment, and equitable access across public healthcare systems. Western European countries generally have advanced imaging and treatment infrastructure, while parts of Eastern Europe continue to address disparities in availability, reimbursement, and specialist density. The region's aging population and structured reimbursement environment continue to make age-related macular degeneration a sustained retinal care priority.

Asia-Pacific is shaped by rapidly aging populations in Japan, China, South Korea, Australia, and parts of Southeast Asia, alongside expanding access to OCT-based diagnostics and retina specialty services in urban centers. Countries with mature eye-care systems are advancing anti-VEGF treatment pathways and imaging-led monitoring, while emerging healthcare systems are working to expand screening, referral capacity, and affordability of intravitreal care. Regional diversity remains substantial, with rural access gaps, variable insurance coverage, and differences in public awareness influencing timely AMD diagnosis and follow-up.

North America has a highly developed AMD care ecosystem supported by broad adoption of retinal imaging, established anti-VEGF protocols, clinical guideline integration, and extensive real-world treatment experience. The United States and Canada have strong specialist networks, but repeated injection visits, adherence challenges, transportation barriers, and coverage-related inequities remain persistent issues for older adults. The region is also central to clinical research activity in neovascular AMD, geographic atrophy, imaging biomarkers, teleophthalmology, and AI-enabled ophthalmology workflows.

Latin America faces the dual challenge of increasing age-related eye disease and uneven specialist access. Brazil and Mexico anchor much of the regional ophthalmology infrastructure, but access to OCT, retina specialists, anti-VEGF treatment, and long-term follow-up varies across public and private systems. Public health strategies that combine diabetic eye disease screening infrastructure with AMD detection could improve retinal disease identification, particularly in urban centers and aging populations.

The Middle East is developing advanced ophthalmology capacity in major urban hubs, supported by tertiary hospitals, specialist eye centers, and growing adoption of retinal imaging. GCC countries are investing in medical infrastructure and digital health, which can support AMD diagnosis and referral pathways. However, awareness of AMD symptoms and routine screening among older adults require continued strengthening, especially outside major cities and in settings where preventive eye care is less consistently accessed.

Africa has the greatest access challenge among the listed regions, with limited retina specialist availability, uneven diagnostic infrastructure, and competing public health priorities. As life expectancy rises in several countries, AMD is expected to become more visible within broader noncommunicable disease and eye health strategies. Integrating AMD awareness into cataract services, community eye-care programs, and teleophthalmology initiatives can help improve early identification while specialist capacity continues to expand.

Key Group Insights Influencing AMD Access

NATO countries include a broad mix of North American and European health systems, many of which have mature ophthalmology networks, established regulatory standards, and advanced retinal imaging capacity. For AMD, NATO-member healthcare systems share priorities around resilient medical supply chains, data protection, digital health governance, veteran and elderly care services, and cross-border research collaboration. Differences in reimbursement and provider capacity remain important, but the group is generally well placed to adopt validated imaging, AI-assisted triage, and durable retinal therapeutics.

G7 countries generally have advanced retina care infrastructure, broad imaging access, and active clinical research ecosystems. The United States, Canada, Japan, Germany, France, Italy, and the United Kingdom have extensive experience with anti-VEGF protocols and are positioned to integrate emerging geographic atrophy therapies, AI tools, and long-acting treatment strategies. Their key operational challenge is sustaining high-quality AMD care while managing clinic workload, aging demographics, and long-term treatment adherence.

The European Union has one of the most structured policy environments for AMD management, supported by regulatory oversight, public health systems, pharmacovigilance, health technology assessment, and clinical guideline implementation. EU countries emphasize evidence-based therapy adoption, reimbursement discipline, and equitable access, while also contributing significantly to research on retinal imaging, geographic atrophy, biosimilars, and real-world outcomes.

BRICS countries represent a heterogeneous AMD environment. China and India face large aging populations and the need to scale retinal screening and specialist capacity, while Brazil and South Africa contend with regional disparities in care access. Russia has established ophthalmology expertise in major cities, though geographic spread can complicate continuity of care. Across BRICS, the common opportunity is to use high-volume healthcare systems, digital imaging, teleophthalmology, and cost-conscious treatment models to improve AMD detection and follow-up.

The GCC is characterized by strong healthcare investment, rapidly modernizing tertiary care, and expanding specialist services in countries such as Saudi Arabia, the United Arab Emirates, Qatar, Kuwait, Bahrain, and Oman. AMD care can benefit from national digital health initiatives, centralized referral systems, and high-capacity hospitals. As populations age and chronic disease burdens rise, the group's priority is to combine advanced treatment access with earlier detection and patient adherence support.

ASEAN countries are experiencing demographic aging at different speeds, creating varied demand for AMD awareness, screening, and treatment services. Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines differ substantially in retina infrastructure and reimbursement coverage, making scalable screening, referral integration, and public-private eye-care collaboration important for improving outcomes. Urban centers often have better access to OCT and anti-VEGF therapy, while rural areas face barriers related to transportation, affordability, and specialist availability.

Key Country Insights for AMD Management

The United States has a highly developed AMD treatment environment with widespread OCT use, large retina specialist networks, and extensive adoption of anti-VEGF therapy, while also facing adherence challenges linked to repeated visits and out-of-pocket burden. China faces a rising AMD burden as its older population expands, and urban hospitals increasingly use advanced retinal imaging and intravitreal therapy, while rural access and specialist distribution remain important constraints. Germany has advanced imaging infrastructure, specialist expertise, and structured reimbursement processes that support evidence-based AMD care. The United Kingdom benefits from organized public healthcare pathways and strong retinal service protocols, although high injection volumes place pressure on ophthalmology clinics.

India has a large and aging population, with AMD care influenced by differences in urban and rural eye-care infrastructure, affordability, and awareness; integration with existing eye health programs can improve detection. Canada emphasizes guideline-based care through provincial health systems, with access shaped by geography, referral pathways, and regional reimbursement policies. Japan has one of the world's oldest populations and a sophisticated ophthalmology ecosystem, making AMD a major retinal disease priority supported by strong imaging adoption and clinical research. France maintains robust ophthalmic services and public reimbursement mechanisms, with growing attention to efficient monitoring and treatment durability.

Mexico has growing ophthalmology capacity in major cities, but disparities between public and private care influence timely diagnosis and continuity of AMD treatment. Brazil is a key Latin American center for retinal care, yet access varies significantly between urban tertiary centers and underserved regions. Italy and Spain both have mature retina practices and aging populations that make AMD a sustained clinical priority, with public health systems focused on balancing innovation, access, and cost-effective care. Australia combines advanced retinal care with public health emphasis on preventable blindness, though distance and access issues affect remote and Indigenous communities. Russia has established ophthalmology centers in major metropolitan areas, while geographic distribution and care continuity remain practical considerations. South Korea has strong medical infrastructure, high technology adoption, and growing emphasis on early diagnosis, imaging-based monitoring, and evidence-based retinal treatment.

Actionable Recommendations for AMD Industry Leaders

Industry leaders should prioritize AMD strategies that combine clinical value, patient access, operational efficiency, and long-term outcomes. First, organizations should invest in earlier detection models by supporting OCT availability, validated AI triage, community screening partnerships, and education for primary eye-care professionals. Earlier identification of intermediate AMD, neovascular conversion, and geographic atrophy progression can improve referral timing and preserve functional vision.

Second, treatment strategies should focus on reducing burden without compromising outcomes. Durable anti-VEGF regimens, treat-and-extend protocols, sustained-release platforms, adherence support, and patient navigation services can help address missed visits and treatment fatigue. Third, stakeholders should build evidence around real-world visual outcomes, safety, durability, quality of life, and health-system efficiency, as payers and providers increasingly require data beyond controlled clinical trials.

Fourth, healthcare organizations should expand equity-focused access planning. This includes affordability pathways, rural teleophthalmology models, mobile imaging, transportation support, and culturally tailored education for older adults and caregivers. Fifth, AI and digital tools should be implemented with clinical validation, bias testing, cybersecurity safeguards, and clear accountability. Finally, leaders should prepare for a more segmented AMD future in which therapy selection, monitoring frequency, and referral urgency are guided by imaging biomarkers, genetic risk, lesion characteristics, comorbidities, and patient preferences.

Research Methodology for AMD Analysis

This executive summary is developed from verified secondary research and evidence-based interpretation of publicly available healthcare, regulatory, clinical, and scientific sources. The methodology emphasizes triangulation across peer-reviewed ophthalmology literature, clinical practice guidelines, public health agencies, regulatory communications, health technology assessment materials, epidemiological studies, and professional society recommendations. Priority is given to sources with transparent methods, recognized clinical relevance, and consistency across independent datasets.

The research approach evaluates AMD through disease classification, epidemiology, diagnostic pathways, treatment standards, technology adoption, regional healthcare infrastructure, and policy context. Evidence on neovascular AMD, geographic atrophy, retinal imaging, anti-VEGF therapy, complement inhibition, teleophthalmology, and AI-based retinal analysis is reviewed to identify durable trends without relying on speculative projections. Regional, group, and country insights are synthesized using demographic aging patterns, healthcare access indicators, clinical infrastructure maturity, reimbursement considerations, and documented eye health priorities.

To maintain analytical integrity, the summary excludes market sizing, market share, and forecasting. It also avoids unverified claims and promotional positioning. Findings are presented as strategic, SEO-optimized narrative insights for decision-makers seeking a reliable overview of the age-related macular degeneration landscape.

Conclusion: Advancing AMD Care Through Innovation and Access

Age-related macular degeneration remains a high-impact retinal disease at the intersection of aging demographics, imaging innovation, therapeutic advancement, and healthcare delivery transformation. The field has moved beyond reactive vision-loss management toward earlier detection, biomarker-driven monitoring, and expanding treatment options for both neovascular AMD and geographic atrophy. Anti-VEGF therapy continues to define wet AMD care, while complement-targeting approaches and next-generation delivery systems are reshaping expectations for late-stage disease management.

The most important opportunities are not limited to new therapies. Sustainable progress in AMD will depend on improving screening access, reducing treatment burden, strengthening adherence, validating AI-enabled workflows, and ensuring that older adults can navigate complex long-term care pathways. Regional disparities remain pronounced, particularly where specialist density, reimbursement, imaging access, and patient awareness are limited. Stakeholders that align scientific innovation with equitable implementation, real-world evidence, and patient-centered care will be best positioned to improve visual outcomes and reduce the societal burden of AMD.

Product Code: MRR-F927BA46233D

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
- 2.2.1. Primary Research
- 2.2.2. Secondary Research
2.3. Research Framework
- 2.3.1. Qualitative Analysis
- 2.3.2. Quantitative Analysis
2.4. Market Size Estimation
- 2.4.1. Top-Down Approach
- 2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
- 4.2.1. Supply-Side Analysis
- 4.2.2. Demand-Side Analysis
- 4.2.3. Stakeholder Analysis
4.3. Market Dynamics
- 4.3.1. Key Drivers
- 4.3.2. Key Restraints
- 4.3.3. Key Opportunities
- 4.3.4. Key Challenges
4.4. Porter's Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
- 4.6.1. Near-Term Market Outlook (0-2 Years)
- 4.6.2. Medium-Term Market Outlook (3-5 Years)
- 4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Age-related Macular Degeneration Market, by Disease Type

7.1. Introduction
7.2. Wet AMD
7.3. Dry AMD

8. Age-related Macular Degeneration Market, by Treatment Modality

8.1. Introduction
8.2. Pharmacotherapy
- 8.2.1. Anti-VEGF Agents
  - 8.2.1.1. Aflibercept
  - 8.2.1.2. Ranibizumab
  - 8.2.1.3. Bevacizumab
  - 8.2.1.4. Brolucizumab
- 8.2.2. Complement Inhibitors
  - 8.2.2.1. Pegcetacoplan
  - 8.2.2.2. Avacincaptad Pegol
- 8.2.3. Tyrosine Kinase Inhibitors
- 8.2.4. Integrin Inhibitors
- 8.2.5. Nutritional Supplementation
8.3. Gene Therapy
8.4. Photodynamic Therapy
8.5. Radiotherapy
8.6. Vision Rehabilitation & Assistive Devices

9. Age-related Macular Degeneration Market, by Baseline Visual Acuity

9.1. Introduction
9.2. >= 20/40
9.3. 20/50 To 20/200
9.4. < 20/200

10. Age-related Macular Degeneration Market, by Route of Administration

10.1. Introduction
10.2. Intravitreal Injection
10.3. Oral Administration
10.4. Topical Ophthalmic

11. Age-related Macular Degeneration Market, by Distribution Channel

11.1. Introduction
11.2. Online Pharmacy
11.3. Offline Pharmacy

12. Age-related Macular Degeneration Market, by End User

12.1. Introduction
12.2. Clinics
12.3. Hospitals
12.4. Specialty Ophthalmic Centers
12.5. Home Care Settings

13. Age-related Macular Degeneration Market, by Region

13.1. Europe
13.2. Asia-Pacific
13.3. North America
13.4. Latin America
13.5. Middle East
13.6. Africa

14. Age-related Macular Degeneration Market, by Group

14.1. NATO
14.2. G7
14.3. European Union
14.4. BRICS
14.5. GCC
14.6. ASEAN

15. Age-related Macular Degeneration Market, by Country

15.1. United States
15.2. China
15.3. Germany
15.4. United Kingdom
15.5. India
15.6. Canada
15.7. Japan
15.8. France
15.9. Mexico
15.10. Brazil
15.11. Italy
15.12. Australia
15.13. Russia
15.14. South Korea
15.15. Spain

16. Competitive Landscape

16.1. Market Share Analysis, 2025
16.2. FPNV Positioning Matrix, 2025
16.3. Market Concentration Analysis, 2025
- 16.3.1. Concentration Ratio (CR)
- 16.3.2. Herfindahl Hirschman Index (HHI)
16.4. Recent Developments & Impact Analysis, 2025
16.5. Product Portfolio Analysis, 2025
16.6. Benchmarking Analysis, 2025

17. Company Profiles

17.1. AbbVie Inc.
17.2. ADVANZ PHARMA group
17.3. Adverum Biotechnologies, Inc.
17.4. Alkeus Pharmaceuticals, Inc.
17.5. Alteogen Inc.
17.6. Alvotech
17.7. Amgen Inc.
17.8. Apellis Pharmaceuticals, Inc.
17.9. Astellas Pharma Inc.
17.10. Bayer AG
17.11. Bio-Thera Solutions, Ltd.
17.12. Coherus Oncology, Inc.
17.13. F. Hoffmann-La Roche AG
17.14. Formycon AG
17.15. INTAS PHARMACEUTICALS LTD.
17.16. Ionis Pharmaceuticals, Inc.
17.17. Johnson & Johnson
17.18. KODIAK SCIENCES INC.
17.19. Lineage Cell Therapeutics, Inc.
17.20. Novartis AG
17.21. Ocular Therapeutix, Inc.
17.22. Ocumension Therapeutics
17.23. Opthea Limited
17.24. Outlook Therapeutics, Inc.
17.25. Oxford Biomedica PLC
17.26. Pfizer Inc.
17.27. Regeneron Pharmaceuticals, Inc.
17.28. REGENXBIO Inc.
17.29. Samsung Bioepis Co., Ltd.
17.30. Sandoz Group AG
17.31. Shanghai Henlius Biotech, Inc.
17.32. STADA Arzneimittel AG
17.33. Stealth BioTherapeutics Inc.
17.34. Teva Pharmaceutical Industries Ltd.